Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C21H22Cl2N4O2 |
|||
Molecular Weight | 433.33 | CAS No. | 869886-67-9 | |
Solubility (25°C)* | In vitro | DMSO | 86 mg/mL (198.46 mM) | |
Ethanol | 86 mg/mL (198.46 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1. | ||||
---|---|---|---|---|---|
Targets |
|
||||
In vitro | In an A375 melanoma cell line containing a b-RAFV600E mutation, Ulixertinib reduces the levels of phosphorylated ERK2 (pERK) and of the phosphorylation of the downstream kinase RSK (pRSK) with IC50 of 4.1/0.14 μM, respectively. Ulixertinib also inhibits A375 cell proliferation with IC50 of 180 nM. [1] |
Kinase Assay:[1] |
|
---|---|
Cell Assay:[1] |
|
Data from [Data independently produced by , , Blood, 2018, 131(18):2047-2059]
Data from [Data independently produced by , , Haematologica, 2018, doi:10.3324/haematol.2018.196931]
Data from [Data independently produced by , , Int J Clin Exp Med, 2016, 9(6):10955-10962.]
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer [ Nature, 2024, 629(8013):927-936] | PubMed: 38588697 |
EHMT2 promotes tumorigenesis in GNAQ/11-mutant uveal melanoma via ARHGAP29-mediated RhoA pathway [ Acta Pharm Sin B, 2024, 14(3):1187-1203] | PubMed: 38486999 |
The mTOR pathway controls phosphorylation of BRAF at T401 [ Cell Commun Signal, 2024, 22(1):428] | PubMed: 39223665 |
Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells [ J Cancer Res Ther, 2024, 20(2):570-577] | PubMed: 38687926 |
ERK mediates interferon gamma-induced melanoma cell death [ Mol Cancer, 2023, 10.1186/s12943-023-01868-x] | PubMed: 37803324 |
Kinase-Modulated Bioluminescent Indicators Enable Noninvasive Imaging of Drug Activity in the Brain [ ACS Cent Sci, 2023, 9(4):719-732] | PubMed: 37122464 |
Kinase-Modulated Bioluminescent Indicators Enable Noninvasive Imaging of Drug Activity in the Brain [ ACS Cent Sci, 2023, 9(4):719-732] | PubMed: 37122464 |
Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition [ Cancer Res, 2023, 83(2):316-331] | PubMed: 36409827 |
Impaired PPARγ activation by cadmium exacerbates infection-induced lung injury [ JCI Insight, 2023, 8(9)e166608] | PubMed: 36928191 |
Impaired PPARγ activation by cadmium exacerbates infection-induced lung injury [ JCI Insight, 2023, 8(9)e166608] | PubMed: 36928191 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.